Evidence map›Paper›PMID 34693548›Full record

ArticleThe Journal of dermatology2022

Annular plaques mimicking Rowell's syndrome in the course of coronavirus disease 2019 mRNA vaccines: An overlooked phenomenon?

Dennis Niebel, Jasmin Wilhelmi, Luka De Vos, Jana Ziob, Kristel Jaschke, Thomas Bieber, Joerg Wenzel, Christine Braegelmann

Abstract read
In one paragraph

Article in The Journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Occurrence of erythema multiforme following COVID-19 vaccination: a review.Clinical and experimental vaccine research · 2023
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dennis NiebelDepartment of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.ORCID https://orcid.org/0000-0003-2069-0486
Jasmin WilhelmiDepartment of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
Luka De VosDepartment of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
Jana ZiobDepartment of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
Kristel JaschkeDepartment of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
Thomas BieberDepartment of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
Joerg WenzelDepartment of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
Christine BraegelmannDepartment of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effective vaccines for prevention of severe course and lethal outcome of coronavirus disease 2019 have been developed and approved in regulatory rolling and fast-track procedures; they are now widely distributed worldwide. Data about cutaneous side-effects of the new mRNA-type vaccines is scant, however. We herein report two similar cases of cutaneous adverse drug reactions (ADR) mimicking Rowell's syndrome that occurred after the first dose of BNT162b2 and mRNA-1273, respectively. Both patients achieved prompt clinical improvement with a short pulse of oral prednisolone and non-steroidal inflammatory drugs. We suspect this phenomenon to occur in a timeframe of 7-14 days after vaccination due to an interferon-γ-driven shift towards type I immunity in susceptible individuals. As rheumatic patients were excluded from phase III clinical trials and as most countries prioritized the elderly population to receive the vaccinations first, cutaneous ADR might become more frequent once the younger part of the population is vaccinated over the course of 2021. Atypical cutaneous ADR might be misinterpreted or overlooked by non-dermatologists. Further studies are required to determine the best suitable vaccine types for individual groups of patients.

Indexed as

COVID-19Erythema Multiforme2019-nCoV Vaccine mRNA-1273AgedBNT162 VaccineCOVID-19 VaccinesHumansmRNA VaccinesRNA, MessengerSARS-CoV-2SyndromeVaccines, Synthetic2019-nCoV Vaccine mRNA-1273BNT162 VaccineCOVID-19 VaccinesmRNA VaccinesRNA, MessengerVaccines, Syntheticadverse eventcoronavirus disease 2019cutaneous lupus erythematosusRowell’s syndromevaccines

Identifiers

PMID34693548
PMCPMC8652474

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.